ZURICH, Jan 21 (Reuters) – An experimental Roche
drug designed to treat the “negative symptoms” of schizophrenia
failed to meet its main goal in two late-stage studies, dealing
a blow to the Swiss drugmaker’s research hopes in the risky area
of brain science.
Results of two Phase III trials found bitopertin in
combination with antipsychotic therapy did not significantly
reduce negative symptoms after 24 weeks of treatment compared
with placebo. A third late-stage study is ongoing.
ZURICH (Reuters) – Demand for chocolate is picking up, boosted by strong sales of gourmet products, the world’s biggest supplier to the industry said on Wednesday, as it blamed capacity constraints and a lull in outsourcing deals for slower growth in its sales volumes.
Barry Callebaut (BARN.S: Quote, Profile, Research, Stock Buzz), which makes chocolate for the likes of Nestle (NESN.VX: Quote, Profile, Research, Stock Buzz) and Mondelez (MDLZ.O: Quote, Profile, Research, Stock Buzz), said on Wednesday consumers in the Americas in particular were flocking to premium chocolates.
ZURICH, Jan 15 (Reuters) – Demand for chocolate is picking
up, boosted by strong sales of gourmet products, the world’s
biggest supplier to the industry said on Wednesday, as it blamed
capacity constraints and a lull in outsourcing deals for slower
growth in its sales volumes.
Barry Callebaut, which makes chocolate for the
likes of Nestle and Mondelez, said on
Wednesday consumers in the Americas in particular were flocking
to premium chocolates.
ZURICH (Reuters) – Swiss drugmaker Roche has found an efficient way for complex antibody drugs to reach and penetrate the brain, raising the possibility of more effective treatments for diseases such as Alzheimer’s.
The innovative brain shuttle technology, which has so far been tested in mice, can cross the blood-brain barrier that has been a key obstacle for researchers working on neurological drugs because it acts as a seal against large molecules such as antibodies.
ZURICH (Reuters) – Pharmaceutical companies including Switzerland’s Novartis and Roche are among those developing a treatment for a specific type of lung cancer, a field that is now so crowded it may impact profits.
A better understanding of the cause of tumors has drawn resources into cancer research at the expense of antibiotics and cardiovascular disease but over-concentration in certain fields could cut commercial rewards, some analysts say.
BERNE (Reuters) – Swiss business groups rallied together on Monday to reject a proposal to re-impose quotas on immigrants from European Union countries, warning the measure would exacerbate a shortage of skilled workers and damage firms’ competitiveness.
Despite the country’s wealth and economic success, immigration is a hot-button issue in Switzerland where the right-wing Swiss People’s Party (SVP) has long blamed rising rents, crowded public transport and higher crime on an influx of foreigners.
BASEL, Dec 6 (Reuters) – Fifteen years ago Ian Parkhill was
diagnosed with a rare muscle-wasting disease that gradually
robbed him of the strength in his thighs.
Now, he struggles to walk. The waning muscle in his arms
will soon hinder his ability to pull himself out of a chair, he
fears, and simple tasks such as holding a pen are increasingly
difficult as the dexterity in his fingers declines.
ZURICH/PARIS (Reuters) – Nestle (NESN.VX: Quote, Profile, Research, Stock Buzz) was selling its 10 percent stake in Swiss fragrance and flavor maker Givaudan (GIVN.VX: Quote, Profile, Research, Stock Buzz) on Friday for as much as 1.08 billion Swiss francs ($1.20 billion), as it concentrates resources on its core food businesses.
The world’s biggest food group cut its sales outlook earlier this year and said it would dispose of underperforming businesses to slim down its sprawling portfolio which spans Perrier bottled water, KitKat chocolate and Gerber baby food.
ZURICH, Dec 6 (Reuters) – ZURICH/PARIS, Dec 6 (Reuters) -
Nestle is selling its 10 percent stake in Swiss
fragrance and flavour maker Givaudan in an effort to
narrow its focus on core operations and clean up its balance
Traders on Friday said the sale managed by Goldman Sachs
through an accelerated book building was being offered at a
price range of 1,150-1,170 Swiss francs a share, valuing the
entire stake at as much as 1.08 billion Swiss francs ($1.20
ZURICH, Nov 24 (Reuters) – Swiss voters rejected a proposal
on Sunday to cap the salaries of top executives at 12 times that
of a company’s lowest wage, heeding warnings from industry
leaders that the measure could harm the country’s economy.
The wealthy nation, which is home to some of the world’s
biggest companies including food group Nestle and
commodities giant Glencore Xstrata, voted 66 percent
against imposing the limit, according to a projection from Swiss